Management of Hepatitis C Infection

  • Authors: Jordan J. Feld, MD, MPH; Hemant Shah, MD, MScCH HPTE (More Info)
  • Editor In Chief: Stefan Zeuzem, MD
  • Last Reviewed: 7/24/18 (What's New)

Summary

  • Glecaprevir/pibrentasvir is approved for treatment of patients with genotype 1-6 HCV infection and compensated cirrhosis[FDA Glecaprevir Pibrentasvir]
    • 12 weeks of therapy indicated for treatment-naive cirrhotic patients infected with any HCV genotype, NS3/4A-experienced cirrhotic patients with genotype 1 HCV infection, and cirrhotic patients with genotype 1, 2, 4, 5, or 6 HCV infection previously treated with interferon, peginterferon, ribavirin, and/or sofosbuvir
    • 16 weeks of therapy indicated for NS5A-experienced cirrhotic patients with genotype 1 HCV infection and cirrhotic patients with genotype 3 HCV infection previously treated with interferon, peginterferon, ribavirin, and/or sofosbuvir

Action required